The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Celgene Corp

Nasdaq: CELG
Last

(U.S.) $131.25

Today's change-0.63 -0.48%
Updated July 31 4:00 PM EDT. Delayed by at least 15 minutes.
 

Celgene Corp

Nasdaq: CELG
Last

(U.S.) $131.25

Today's change-0.63 -0.48%
Updated July 31 4:00 PM EDT. Delayed by at least 15 minutes.

Celgene Corp down (U.S.)$0.63

Celgene Corp closed lower Friday, dropping (U.S.)$0.63 or 0.48% to (U.S.)$131.25. Shares have lost 2.71% over the last five days, but have gained 17.33% over the last year to date. This security has outperformed the S&P 500 by 41.63% during the last year.

Key company metrics

  • Open(U.S.) $132.83
  • Previous close(U.S.) $131.88
  • High(U.S.) $133.00
  • Low(U.S.) $130.77
  • Bid / Ask-- / --
  • YTD % change+17.33%
  • Volume3,546,702
  • Average volume (10-day)5,252,645
  • Average volume (1-month)5,464,560
  • Average volume (3-month)4,628,242
  • 52-week range(U.S.) $83.16 to (U.S.) $140.72
  • Beta1.00
  • Trailing P/E49.73×
  • P/E 1 year forward27.32×
  • Forward PEG1.08×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.64
Updated July 31 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+26.08%

Based on its net profit margin of 26.08%, Celgene Corp is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.60%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue2,2782,0812,0861,982
Total other revenue--------
Total revenue2,2782,0812,0861,982
Gross profit2,1771,9771,9821,885
Total cost of revenue10110410398
Total operating expense1,8621,2241,3341,338
Selling / general / administrative617529544498
Research & development1,110506585675
Depreciation / amortization64646464
Interest expense (income), net operating--------
Unusual expense (income)-2921384
Other operating expenses, total--------
Operating income416857752645
Interest income (expense), net non-operating-48-63-64-64
Gain (loss) on sale of assets--------
Other--------
Income before tax471827711578
Income after tax356719614509
Income tax, total1151089769
Net income356719614509
Total adjustments to net income--------
Net income before extra. items356719614509
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items356719614509
Inc. avail. to common incl. extra. items356719614509
Diluted net income356719614509
Dilution adjustment--------
Diluted weighted average shares825834835833
Diluted EPS excluding extraordinary itemsvalue per share0.430.860.740.61
Dividends per sharevalue per share--0.00--0.00
Diluted normalized EPSvalue per share0.400.880.770.61